Over the years, the research published by The American Journal of Managed Care has been key in understanding the link between value and outcomes and what is paid for healthcare services, said Charles N. Kahn III, MPH, president and CEO of the Federation of American Hospitals.
president and CEO of the Federation of American Hospitals.
Over the years, the research published by The American Journal of Managed Care has been key in understanding the link between value and outcomes and what is paid for healthcare services, said Charles N. Kahn III, MPH,
Transcript (slightly modified for readability)
I wish the Journal a happy anniversary. And I do that both as someone who has served many, many years on the editorial board, but more importantly as someone who really respects the work of the Journal and understands the importance of all that has been done in these articles over the years and the research that goes into the articles.
We are still looking for that link between value and outcomes and what's paid for healthcare services so that we can be assured that we are getting the right healthcare for the right price. And the work and research done by those who have been contributors to articles in the Journal over the years have pushed the knowledge. A lot of value-based purchasing and value-based insurance understanding of them has come from the research in the Journal.
I think it has been great work—important work. I think we're not quite there yet in terms of understanding how we should pay for healthcare services, but clearly the Journal has played key role over the years in helping us move in the right direction.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More